Most people think about cannabinoids one at a time. The science doesn’t work that way. When you consume a full-spectrum product, CBD is simultaneously reducing how strongly THC can activate CB1 receptors. CBG is hitting those same receptors from a different structural angle as a partial agonist. CBN is extending the sedative tail. Beta-caryophyllene is activating CB2 through its own independent pathway. This isn’t the entourage effect as a marketing phrase. It’s four or five distinct pharmacological events happening in parallel at different receptor sites. Understanding which ones and why changes how you read a COA and choose a product.
🧪 Lab Tested | 👩💼 Woman-Owned | 🏆 Est. 2017
The Endocannabinoid System as a Modulation Network
The endocannabinoid system (ECS) is primarily a retrograde signaling network. Most neurotransmitter systems fire forward (neuron A releases a signal, neuron B receives it). The ECS works backwards. Post-synaptic neurons produce endocannabinoids on demand, which travel back across the synapse to modulate how much neurotransmitter the pre-synaptic neuron is releasing. The entire system is built for fine-tuning, not activation.
This retrograde architecture explains why cannabinoid interactions are so consequential. CB1 receptors are positioned at synapses throughout the brain specifically to act as volume controls on neuronal signaling. When multiple compounds hit the same volume control from different angles at the same time, the resulting effect isn’t simply additive. The receptor’s response depends on which compounds are present, at what concentrations, and through which binding mechanisms they’re acting.
CBD and THC are a good example of why this matters. THC activates CB1 as a full agonist. CBD acts as a negative allosteric modulator at CB1. It doesn’t bind the same site THC uses, but it changes the receptor’s shape in a way that reduces how effectively THC can activate it. So CBD isn’t just doing its own thing alongside THC. It’s actively modifying the THC experience at the receptor level. The two compounds together produce a different pharmacological event than either alone.
How Each Major Cannabinoid Hits Each Receptor
The table below maps the documented receptor interactions for the six cannabinoids most commonly present in full-spectrum hemp products. “Activates” means the compound binds and activates the receptor. “Modulates” means it changes how the receptor responds to other compounds without directly activating it. “Inhibits enzyme” refers to blocking enzymes that break down endocannabinoids, extending their natural activity.
| Cannabinoid | CB1 | CB2 | 5-HT1A | TRPV1 | FAAH | GABA-A |
|---|---|---|---|---|---|---|
| THC (Delta-9) | Full agonist | Partial agonist | Weak | Activates | Minimal | Indirect |
| CBD | Neg. allosteric mod. | Partial agonist | Activates | Activates / desensitizes | Inhibits | Indirect |
| CBG | Partial agonist | Partial agonist | Activates | Activates | Inhibits | Weak |
| CBN | Partial agonist | Partial agonist | Minimal | Weak | Minimal | Unclear |
| CBC | Weak direct | Partial agonist | Weak | Activates | Minimal | Minimal |
| Delta-8 THC | Partial agonist | Partial agonist | Weak | Weak | Minimal | Indirect |
A few things stand out in this table. CBD is the only compound with a negative allosteric modulator classification at CB1. It actively damps the receptor rather than activating it. CBG is the cannabinoid with the broadest receptor footprint after CBD, activating CB1, CB2, and 5-HT1A while also inhibiting FAAH. CBN’s receptor profile is narrow: mainly CB1 and CB2 partial agonism, nothing else at meaningful activity. Delta-8 THC is a partial agonist everywhere Delta-9 is a full agonist, which explains its lower potency ceiling.
Key Cannabinoid Pairings and What They Do
CBD + THC (Delta-9)
The most studied interaction in cannabinoid pharmacology
CBD’s negative allosteric modulation at CB1 means it physically changes the receptor’s conformation in a way that reduces THC’s maximum binding efficacy. The result at typical full-spectrum ratios (high CBD, trace THC) is that THC’s psychoactive intensity is dampened and the anxiety ceiling is raised. CBD’s simultaneous 5-HT1A activation adds an independent anxiolytic effect on top. Users who find Delta-9 anxiety-prone often find full-spectrum CBD+trace-THC products more manageable. Clinically, a 1:1 CBD:THC ratio has been studied specifically for its reduced anxiety and psychoactivity profile compared to THC alone.
CBG + CBD
Convergent 5-HT1A activation with independent FAAH inhibition
Both CBD and CBG inhibit FAAH (the enzyme that breaks down anandamide). When both are present, their combined FAAH inhibition is greater than either alone, producing a more substantial increase in circulating anandamide (the body’s own endocannabinoid). Both compounds also activate 5-HT1A through different binding mechanisms, creating a more stable serotonin receptor activation than either produces independently. CBG also adds partial CB1 agonism that CBD lacks, giving the combination a mild direct endocannabinoid system activation layer that pure CBD products don’t provide.
CBN + THC
Sedative synergy via overlapping partial agonism
CBN appears in aged cannabis as THC oxidizes over time. It’s a partial CB1 agonist with lower potency than THC, but when both are present, the combined CB1 and CB2 occupancy extends the duration and deepens the sedative quality of the experience. Preliminary research suggests CBN’s most pronounced effects emerge specifically in combination with THC rather than in isolation. Old, high-CBN flower is described as “sleepy” while CBN isolate products show less dramatic standalone sedation. CBN contributes meaningfully to the tail end of a full-spectrum experience’s duration.
CBC + CBD + CBG
Anti-inflammatory support from multiple CB2 and TRPV1 pathways
Cannabichromene (CBC) is a weak direct CB1 ligand but a meaningful CB2 partial agonist and TRPV1 activator. In combination with CBD’s CB2 partial agonism and CBG’s CB2 activity, three cannabinoids are converging on CB2 receptors through distinct structural approaches. TRPV1 convergence (CBD desensitizes it; CBC activates it; CBG activates it) produces a complex anti-inflammatory interaction at the transient receptor potential channel that none of the three could produce alone. CBC is often below 0.5% in hemp products but still contributes to the CB2 activation profile in the trace amounts where it appears.
Four Interaction Mechanisms Worth Understanding
Allosteric Modulation
An allosteric modulator binds a receptor at a site separate from the primary binding site and changes the receptor’s shape and responsiveness. CBD is a negative allosteric modulator at CB1: it doesn’t compete with THC for the same binding site, but it changes how effectively THC can activate the receptor once it binds. The practical result is that CBD and THC can both be present and active at CB1 simultaneously, with CBD continuously reducing the ceiling of THC’s effect. No other commonly discussed cannabinoid has this property at CB1.
Partial vs Full Agonism
A full agonist (THC at CB1) activates a receptor to its maximum possible response at saturating concentrations. A partial agonist (CBG at CB1, Delta-8 at CB1) activates the same receptor but only to a fraction of its maximum response ceiling, regardless of dose. When a partial and full agonist compete for the same receptor, the partial agonist can actually reduce the full agonist’s effect at high concentrations. Not because it blocks it, but because it occupies receptor sites the full agonist would otherwise fill. At low-to-moderate THC doses, CBG co-administration adds a gentler layer of CB1 activity; at high THC doses, CBG can begin to moderate the intensity.
FAAH Inhibition Stacking
Fatty acid amide hydrolase (FAAH) is the enzyme that degrades anandamide, the body’s primary endogenous CB1 agonist. CBD inhibits FAAH with documented efficacy. CBG also shows FAAH-inhibiting activity. When both are present, their combined enzymatic inhibition extends anandamide’s time in the synapse more than either compound alone achieves. Elevated anandamide produces its own calm, mildly mood-brightening effect through CB1 and 5-HT1A receptors, without the psychoactive intensity of direct THC activation. Products with meaningful CBD and CBG together are accessing the body’s own endocannabinoid system more efficiently than CBD-only products.
Receptor Convergence
Multiple cannabinoids and terpenes activating the same receptor type through different structural binding mechanisms produce a more stable, sustained activation than a single compound binding alone. The 5-HT1A receptor is the clearest example: CBD, CBG, limonene (a terpene), and linalool (a terpene) all activate 5-HT1A. They do so through different binding sites. The combined multi-source activation keeps the receptor engaged in a way that a single agonist cannot maintain.
What the Minor Cannabinoids Contribute
CBG, CBN, and CBC are present at low concentrations in most hemp products, typically under 1% individually, but they are pharmacologically active at those concentrations rather than neutral. The relevant question for each isn’t “is it present?” but “what does it contribute to the overall receptor interaction profile?”
CBG is the broadest-acting minor cannabinoid in hemp. Its CB1 partial agonism, CB2 partial agonism, 5-HT1A activation, and FAAH inhibition give it a wider receptor footprint than any minor cannabinoid. It acts as a mild tone-setter for the overall experience: slightly activating through 5-HT1A and FAAH, slightly moderating at high THC concentrations through partial agonism competition, physically comfortable through CB2. A full-spectrum product with meaningful CBG (above 0.5%) behaves differently from one without it even if the CBD concentration is identical.
CBN contributes primarily to sedation and duration. Its narrow receptor profile (mainly CB1 and CB2 partial agonism) means it doesn’t add the mood or anti-inflammatory dimensions that CBG does. CBN’s contribution comes through extending the occupancy of CB1 and CB2 receptors in the later phase of the experience. It deepens and lengthens the tail rather than shaping the peak. It’s found at higher concentrations in aged or heated products as THC oxidizes.
CBC adds anti-inflammatory physical comfort through CB2 partial agonism and TRPV1 activity. Like CBN, its effects are most pronounced in combination with other cannabinoids rather than in isolation. Its TRPV1 activation contributes to the anti-inflammatory pathway that beta-caryophyllene (a terpene) also accesses, creating cross-compound convergence at the same anti-inflammatory receptor targets.
A product labeled “full spectrum” that shows only CBD on the COA with everything else at trace levels is missing the interactions described above. CBG, CBN, and CBC need to appear at or above 0.1% individually to contribute meaningfully to the multi-receptor interaction profile. Total minor cannabinoid content below 0.5% combined suggests a product that is functionally close to CBD isolate even with the full-spectrum label.
How to Use This on a COA
Cannabinoid interaction quality in a product can be estimated from three sections of a COA: the cannabinoid panel, the terpene panel, and total content.
Cannabinoid panel: count active minor cannabinoids. Look for CBG, CBN, and CBC each at or above 0.1%. A product with CBD at 25mg plus CBG at 3mg, CBN at 1mg, and CBC at 0.5mg per serving has a meaningfully different receptor interaction profile than a product with CBD at 25mg and everything else below detection. The combination unlocks FAAH stacking, CB2 multi-source activation, and 5-HT1A convergence simultaneously.
Terpene panel: confirm the entourage layer is present. Total terpenes above 1% indicates meaningful terpene contribution to the receptor interaction picture. Beta-caryophyllene above 0.3% adds independent CB2 activation. Limonene and linalool above 0.5% together add 5-HT1A convergence. Myrcene above 0.5% adds FAAH-adjacent activity and delivery efficiency. Below 0.5% total terpenes, the terpene layer is largely absent from the interaction profile regardless of how the product is labeled.
CBD:CBG ratio. A 10:1 or better CBD:CBG ratio (for example, 25mg CBD with 2.5mg CBG per serving) provides the CBG concentration needed for meaningful FAAH stacking and 5-HT1A convergence. Below 20:1, the CBG is present at pharmacologically marginal concentrations. Products specifically formulated with higher CBG (5:1 or lower ratios) produce a noticeably different receptor interaction profile from standard CBD-dominant products.
All TribeTokes COAs are available at tribetokes.com/certificates-of-analysis. The cannabinoid panel lists each compound by concentration, and the terpene panel confirms whether the full terpene layer is present.
Frequently Asked Questions
Yes, through several documented mechanisms. CBD modulates how THC activates CB1 receptors through negative allosteric modulation. CBG and Delta-8 compete with THC as partial agonists at the same receptor sites, which can moderate THC’s effect at higher concentrations. CBD and CBG together inhibit FAAH more effectively than either alone, extending anandamide’s activity. Multiple cannabinoids converging on CB2 and 5-HT1A receptors through different binding mechanisms produce more stable receptor activation than any single compound achieves independently.
CBD acts as a negative allosteric modulator at CB1 receptors. It binds at a site separate from where THC binds and changes the receptor’s shape in a way that reduces how effectively THC can activate it. The practical effect is a lower psychoactive ceiling and reduced anxiety from equivalent THC doses when CBD is also present. CBD also activates 5-HT1A serotonin receptors independently, adding its own anxiolytic effect on top of the CB1 modulation. Products with meaningful CBD alongside THC feel less intense and more manageable than THC alone at the same milligram dose.
They serve different functions rather than one being better than the other. CBD’s most notable property at CB1 is its negative allosteric modulation. It damps THC’s effect. CBG is a partial agonist at CB1, adding mild direct activity that CBD doesn’t provide. CBG also inhibits FAAH like CBD does, and their combined FAAH inhibition is greater than either alone. Most full-spectrum products contain both, and their interaction produces effects neither creates independently. The more useful question is whether a product contains meaningful amounts of both at an active ratio.
CBN is a partial CB1 and CB2 agonist, and its sedative reputation comes primarily from its effect in combination with THC rather than in isolation. Research suggests CBN’s sedative quality is most pronounced when it’s present alongside THC. The two partial and full agonists together produce a deeper and longer-lasting CB1/CB2 occupancy than THC alone. CBN also appears in products where it has been formed through THC oxidation, which means high-CBN products have typically also been aged in ways that affect other aspects of the compound profile.
Fatty acid amide hydrolase (FAAH) is the enzyme responsible for breaking down anandamide, the body’s primary endogenous CB1 agonist. When FAAH is inhibited, anandamide stays active in the synapse longer, producing its own mild calming and mood-brightening effects through CB1 and 5-HT1A receptors. CBD inhibits FAAH. CBG also inhibits FAAH. When both are present, their combined FAAH inhibition is more effective than either alone, raising circulating anandamide to a higher level than single-compound products achieve.
Allosteric modulation means binding a receptor at a site different from where the primary agonist binds and changing the receptor’s shape and responsiveness. Negative allosteric modulation means the shape change reduces the receptor’s response to its primary agonist. CBD is a negative allosteric modulator at CB1: it binds a separate site on the receptor and reduces how effectively THC activates it, without blocking THC from binding. The result is that CBD and THC can be present simultaneously at CB1, with CBD continuously lowering the ceiling of THC’s effect without preventing it.
Yes, at the concentrations present in full-spectrum hemp products. CBG at 0.5% per serving (roughly 2–5mg depending on the product) produces meaningful FAAH inhibition and 5-HT1A activation. CBN at 0.3–1mg contributes to CB1 and CB2 partial agonism that extends the interaction profile’s duration. CBC at trace levels adds CB2 and TRPV1 activity. The relevant threshold for each is whether it reaches a pharmacologically active concentration (which varies by compound) rather than whether it’s present at all.
Look at the COA cannabinoid panel for multiple compounds at active concentrations: CBG above 0.1% (ideally above 0.3%), CBN and CBC at trace-to-low levels above the detection floor, and CBD as the dominant cannabinoid. Then check the terpene panel for total terpenes above 1% to confirm the terpene layer is present. A product showing CBD plus meaningful CBG plus detectable CBN and CBC, with a full terpene panel, has the multi-receptor interaction profile described in this article. A product showing CBD only with everything else at ND is functionally close to isolate regardless of how it’s labeled. All TribeTokes COAs are at tribetokes.com/certificates-of-analysis.
Full-Spectrum Means All of This Is Working at Once. COA on Every Batch.
Third-party tested. ISO-accredited lab. Woman-owned since 2017.